Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 155Rituximab 148Etoposide 84fludarabine phosphate 73Peripheral Blood Stem Cell Transplantation 68Mycophenolic Acid 63Busulfan 62Filgrastim 59Melphalan 58Tacrolimus 54Whole-Body Irradiation 51Cytarabine 46fludarabine 45Radiotherapy 43Methotrexate 41Granulocyte Colony-Stimulating Factor 41Cyclosporine 41Vincristine 35Antilymphocyte Serum 35Carmustine 33Doxorubicin 29Prednisone 26Thiotepa 25Bendamustine Hydrochloride 24Methylprednisolone 22Ifosfamide 22Dexamethasone 22thymoglobulin 21sargramostim 20plerixafor 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Non-Hodgkin × pidilizumab × Clear all
NCT00532259 2014-09-12

CT-011 MAb in DLBCL Patients Following ASCT

CureTech Ltd

Phase 2 Completed
72 enrolled 9 charts
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡